Abstract | BACKGROUND: Intravenous iron supplementation is an integral part of the management of anemia in patients with chronic kidney disease. Traditionally, this has been administered as an infusion over 1 or more hours, which requires the use of intravenous fluids and administration tubing, along with extra demands on patient and nursing time. METHODS: RESULTS: The most common adverse event was a mild and transient metallic taste that occurred during 412 injections (17.9%); in no case was this of significant distress to the patient. Excluding this, 2,240 injections (97.5%) proceeded uneventfully, and no case of phlebitis was recorded. Adverse events other than metallic taste were recorded in association with 57 injections (2.5%). Seven of these were caused by an acute anaphylactoid reaction to the intravenous iron. All 7 acute reactions resolved completely within 30 minutes with no sequelae, and none required hospitalization. The remaining 50 adverse events consisted of pain during the injection (n = 31), pain after the injection with or without some bruising (n = 9), nausea/gastrointestinal symptoms (n = 3), lethargy (n = 4), and lightheadedness (n = 3). CONCLUSION: Administration of 200 mg of iron sucrose as an intravenous bolus injection over 2 minutes is a practical dosing regimen in patients with chronic kidney disease, resulting in considerable savings in time and cost.
|
Authors | Iain C Macdougall, Alison Roche |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 46
Issue 2
Pg. 283-9
(Aug 2005)
ISSN: 1523-6838 [Electronic] United States |
PMID | 16112047
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ferric Compounds
- Erythropoietin
- Ferric Oxide, Saccharated
- Glucaric Acid
|
Topics |
- Adult
- Aged
- Anaphylaxis
(etiology)
- Anemia, Hypochromic
(drug therapy, etiology, prevention & control)
- Chronic Disease
- Cohort Studies
- Dysgeusia
(chemically induced)
- Erythropoietin
(therapeutic use)
- Female
- Ferric Compounds
(administration & dosage, adverse effects, therapeutic use)
- Ferric Oxide, Saccharated
- Glucaric Acid
- Graft Rejection
- Humans
- Hypotension
(chemically induced)
- Injections, Intravenous
- Kidney Diseases
(complications, surgery, therapy)
- Kidney Transplantation
- Male
- Middle Aged
- Peritoneal Dialysis
- Peritoneal Dialysis, Continuous Ambulatory
- Prospective Studies
|